The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer.
The time taken to obtain the results of BRCA1/2 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months. The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients. The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients' genetic status and improve their mental well-being.
The main objective of this project is to compare the results obtained with an ultra-fast kit developed by O.N.T with those obtained with the current gold standard, NGS sequencing.
Age ≥ 18 years
Indication for oncogenetic consultation with a wide panel test including BRCA1/2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer.
The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email.
Diagnosis of the disease ≤ 6 months
Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires
Patients who do not have an email address and/or do not have internet access or tools to connect to the internet
Women who are pregnant, may become pregnant or are breast-feeding
Persons deprived of their liberty or under guardianship (including curatorship)
Breast cancer with an indication for theranostic BRCA1/2 analysis or diagnostic BRCA1/2 analysis
Cohort
Prospective
Questionnaires
Other intervention3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients : * STAI-Y (State-Trait Anxiety Inventory) * Patient's Questionnaire * Practitioner's questionnaire
Communication of the results of the BRCA1/2 ultra rapid test
Other interventionCommunication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
Compare the results obtained with an ultra-rapid kit BRCA1/2 with those obtained with the current gold standard, by checking the sensitivity, specificity and the rate of patients correctly classified for BRCA1 and 2 status
The main objective will be to determine the rate of misclassified patients by pooling the 2 arms, false positives and false negatives. * True positives (VP) : patients presenting a BRCA 1 or 2 mutation with the ultrafast BRCA1/2 test and the gold standard. * False positives (FP) : patients with a BRCA 1 or 2 mutation using the BRCA1/2 ultrafast test and no BRCA 1 or 2 mutation using the gold standard. * True negatives (VN) : patients with no BRCA 1 or 2 mutation using the BRCA1/2 ultrafast test and the gold standard. * False negatives (FN) : patients without a BRCA 1 or 2 mutation using the BRCA1/2 ultrafast test and with a BRCA 1 or 2 mutation using the standard test. WELL classified = VP + VN, poorly classified= FP+ FN FPs will generate anxiety, and FNs will lead to a loss of chance for patients if the ultrafast BRCA1/2 test (nanopore test) is used exclusively instead of the gold standard. The overall number of misclassified patients must therefore be limited.
Evaluate the sensitivity and specificity of the ultra-rapid BRCA1/2 test
Evaluate the sensitivity and specificity of the ultra-rapid BRCA1/2 test (nanopore test) compared with the standard BRCA1/2 test (gold standard).
To assess the impact on patients' mental well-being (anxiety or reassurance) using the State-Trait Anxiety Questionnaire (STAI-Y)
Anxiety will be assessed in each arm using the State-Trait Anxiety Questionnaire (STAI-Y) at 4 different time points: * After the patient has not objected to taking part in the TURBO study at the first consultation (before randomization); * 1-2 weeks after inclusion. The questionnaire will be e-mailed to patients. The questionnaire must be completed before the results of the BRCA1/2 ultrafast test (nanopore test) are communicated to patients in the experimental group. * 4 weeks after inclusion. The questionnaire will be sent by email. * 8 - 12 weeks after inclusion, during the consultation for the communication of test results with the gold standard, before the communication of results.
Evaluate clinician satisfaction with satisfaction scale used in genetic counselling
Clinician satisfaction (oncogeneticist and oncologist) and acceptance of the BRCA1/2 ultrafast test (nanopore test) will be evaluated in both arms using a questionnaire to assess clinician satisfaction at 2 different times for each practitioner involved in patient follow-up: * When the first patient is unopposed; * At the last patient's discharge.
Evaluate patient satisfaction used in genetic counselling
Patient satisfaction will be assessed in both arms using a satisfaction scale used in genetic counselling at two different times: * After the patient has made no objection to participating in the TURBO study during the first consultation (before randomization); * 8 - 12 weeks after inclusion, before the consultation for the gold standard test results.
Click on the lead sponsor to view all of their trials.
